This study focuses on people who have advanced stomach or esophageal cancer that has spread. The purpose of the study is to compare the usual treatment alone (the combination of 2 drugs, paclitaxel and ramucirumab) to the usual treatment plus a drug called nivolumab. The addition of nivolumab to the usual treatment could stop the cancer from spreading, but it may also cause side effects. Researchers aim to determine whether patients experience a longer, shorter, or same amount of time without the disease getting worse (progression) than patients taking the standard treatment alone, as well as whether they live longer with the addition of nivolumab. Participants will be randomly assigned to 1 of 2 groups. Group 1 will receive paclitaxel, ramucirumab, and nivolumab (the usual treatment plus nivolumab); Group 2 will receive paclitaxel and ramucirumab alone. While paclitaxel and ramucirumab are approved by the U.S. Food and Drug Administration, the combined use of paclitaxel, ramucirumab, and nivolumab is considered experimental.
What is the full name of this clinical trial?
S2303: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS; 1 Advanced Gastric and Esophageal Adenocarcinoma